Source: CureToday articles
Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.
Recent Content
- Engineered Extracellular Vesicles May Be a New Approach to Treating MASH
- Blocking IL6 Pathway May Prevent Progression of Skin Ulcers in Calciphylaxis CKD-Related Disease
- Expert: Dual Interaction is Present Between Epilepsy and Menopause
- Pre-Treatment Baseline Screening for Breast Cancer–Related Lymphedema
- Dosing of PAS-004 Begins in Patients in MAPK-Driven Tumors
- Barriers to Bridging Clinical Trial Data to Routine Pharmacy Practice
- Enhancing Patient Care Through Multidisciplinary Team Collaboration in Management of NSCLC
- CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma
- Asembia AXS25: Navigating the Future of Cell and Gene Therapies
- Asembia AXS25: Addressing Health Equity in Specialty Pharmacy Services